Juan Jesús
Cruz Hernández
Profesor Emérito Honorífico


Universidad de Valladolid
Valladolid, EspañaPublicacións en colaboración con investigadores/as de Universidad de Valladolid (11)
2023
-
Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis
Chinese Clinical Oncology, Vol. 12, Núm. 6
2022
-
Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy
Frontiers in bioscience (Landmark edition), Vol. 27, Núm. 3, pp. 88
-
Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis
Biomedicines, Vol. 10, Núm. 2
2021
-
Dopamine receptors and the kidney: An overview of health-and pharmacological-targeted implications
Biomolecules, Vol. 11, Núm. 2, pp. 1-16
-
Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors
Life, Vol. 11, Núm. 12
-
Resistance to immune checkpoint inhibitors secondary to myeloid-derived suppressor cells: A new therapeutic targeting of haematological malignancies
Journal of Clinical Medicine, Vol. 10, Núm. 9
-
The influence of diet and probiotics on the response of solid tumours to immunotherapy: Present and future perspectives
Applied Sciences (Switzerland), Vol. 11, Núm. 18
2020
-
Clinical perspective and translational oncology of liquid biopsy
Diagnostics, Vol. 10, Núm. 7
-
Liquid biopsy as novel tool in precision medicine: Origins, properties, identification and clinical perspective of cancer’s biomarkers
Diagnostics, Vol. 10, Núm. 4
2013
-
Incidence of -93 MLH1 promoter polymorphism in familial and sporadic colorectal cancer
Colorectal Disease, Vol. 15, Núm. 3
2003
-
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: A high proportion of mutations unique to Spain and evidence of founder effects
Human Mutation, Vol. 22, Núm. 4, pp. 301-312